The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

Denmark’s Novo Nordisk said late Friday that the US Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) ...

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer ... recommending the approval of Alhemo (concizumab) for ...

Construction has already begun on the Ozempic-producer’s new Danish production facility and 40,000m² warehouse.

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) bleeding prevention injection for patients with rare clotting disorders ...

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

recommending the approval of Alhemo (concizumab) for haemophilia A or B with inhibitors. A final decision is expected soon. Alhemo is not approved in the United States. Novo Nordisk is trading ...

Denmark-based pharma giant Novo Nordisk has announced plans to invest ... The company’s haemophilia portfolio includes Alhemo (concizumab) and its antibody asset Mim8, with the Phase III ...